Aldo-keto reductase 1B10 as a Carcinogenic but Not a Prognostic Factor in Colorectal Cancer

Ye, Xu; Wang, Tao; Zhong, Liyuan; Farrés, Jaume; Xia, Jiliang; Zeng, Xi; Cao, Deliang

doi:10.7150/jca.91064



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2024; 15(6):1657-1667. doi:10.7150/jca.91064 This issue Cite

Research Paper

Aldo-keto reductase 1B10 as a Carcinogenic but Not a Prognostic Factor in Colorectal Cancer

Xu Ye¹, Tao Wang², Liyuan Zhong², Jaume Farrés³, Jiliang Xia², Xi Zeng^2✉, Deliang Cao^2✉

1. Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan 410031, China.
2. Hunan Province Key Laboratory of Cancer Cellular and Molecular Pathology, Cancer Research Institute, University of South China Hengyang Medical College. 28 W Changsheng Road, Hengyang, Hunan 421009, China.
3. Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, E-08193, Bellaterra, Barcelona, Spain.

Citation:

Ye X, Wang T, Zhong L, Farrés J, Xia J, Zeng X, Cao D. Aldo-keto reductase 1B10 as a Carcinogenic but Not a Prognostic Factor in Colorectal Cancer. J Cancer 2024; 15(6):1657-1667. doi:10.7150/jca.91064. https://www.jcancer.org/v15p1657.htm

Other styles

Abstract

Colorectal cancer (CRC) is the leading cause of cancer death, but little is known about its etiopathology. Aldo-keto reductase 1B10 (AKR1B10) protein is primarily expressed in intestinal epithelial cells, but lost in colorectal cancer tissues. This study revealed that AKR1B10 may not be a prognostic but an etiological factor in colorectal tumorigenesis. Using a tissue microarray, we investigated the expression of AKR1B10 in tumor tissues of 592 colorectal cancer patients with a mean follow-up of 25 years. Results exhibited that AKR1B10 protein was undetectable in 374 (63.13%), weakly positive in 146 (24.66%), and positive 72 (12.16%) of 592 tumor tissues. Kaplan-Meier analysis showed that AKR1B10 expression was not correlated with overall survival or disease-free survival. Similar results were obtained in various survival analyses stratified by clinicopathological parameters. AKR1B10 was not correlated with tumor T-pathology, N-pathology, TNM stages, cell differentiation and lymph node/regional/distant metastasis either. However, AKR1B10 silencing in culture cells enhanced carbonyl induced protein and DNA damage; and in ulcerative colitis tissues, AKR1B10 deficiency was associated acrolein-protein lesions. Together this study suggests that AKR1B10 downregulation may not be a prognostic but a carcinogenic factor of colorectal cancer.

Keywords: Colorectal cancer, AKR1B10, Biomarker, Tissue microarrays, and DNA damage

Citation styles

APA

Ye, X., Wang, T., Zhong, L., Farrés, J., Xia, J., Zeng, X., Cao, D. (2024). Aldo-keto reductase 1B10 as a Carcinogenic but Not a Prognostic Factor in Colorectal Cancer. Journal of Cancer, 15(6), 1657-1667. https://doi.org/10.7150/jca.91064.

ACS

Ye, X.; Wang, T.; Zhong, L.; Farrés, J.; Xia, J.; Zeng, X.; Cao, D. Aldo-keto reductase 1B10 as a Carcinogenic but Not a Prognostic Factor in Colorectal Cancer. J. Cancer 2024, 15 (6), 1657-1667. DOI: 10.7150/jca.91064.

NLM

CSE

Ye X, Wang T, Zhong L, Farrés J, Xia J, Zeng X, Cao D. 2024. Aldo-keto reductase 1B10 as a Carcinogenic but Not a Prognostic Factor in Colorectal Cancer. J Cancer. 15(6):1657-1667.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.